Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...
The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...
Zacks Investment Research on MSN
Investors heavily search Novo Nordisk A/S (NVO): Here is what you need to know
Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...
The issues are piling on for the healthcare leader, but this one is nowhere near insurmountable.
Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...
AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) was approved in the U.S. for the treatment of adult ...
Novo Nordisk has intensified its legal push in India by filing a plea against Sun Pharma, seeking to delay competition in the ...
Denmark: Novo Nordisk and Akero Therapeutics have announced that Novo Nordisk's acquisition of Akero has been completed.With ...
The Delhi High Court has allowed Sun Pharma to manufacture and export semaglutide-based drugs to countries where Novo Nordisk ...
The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...
Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The ...
Novo Nordisk A/S (NYSE:NVO) is one of the best pharma stocks to invest in. Argus analyst Jasper Hellweg downgraded Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback